GlassScriptPhysician profile
Sarah S Weeks
NPI 1134570096
$5,874.94
in general payments reported to CMS, 2019-2025
26 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $32.60 · 2021: $1,477 · 2022: $1,017 · 2023: $880 · 2024: $820 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,855 · Entertainment: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,854.82 |
| Entertainment | $111.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visionary Optics LLC | $980.00 | 2021 | |
| Abbvie INC. | $794.56 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Coopervision INC. | $534.62 | 2022-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Biotissue Holdings INC. | $497.46 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $424.38 | 2019-2025 | Cequa |
| Glaukos Corporation | $416.76 | 2022-2025 | Idose, Istent Infinite Trabecular Micro-Bypass System Model Is3, Idosetr |
| Bausch & Lomb Americas INC. | $304.42 | 2022-2025 | Infuse, Xiidra, Vyzulta |
| Allergan, INC. | $300.50 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $298.68 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $170.18 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $157.52 | 2019-2022 | |
| Dompe US, INC. | $155.70 | 2019-2025 | Oxervate |
| Alcon Vision LLC | $119.74 | 2025 | Clareon Panoptix Pro, Clareon |
| Optos, INC. | $111.99 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Optovue, INC. | $101.40 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $99.59 | 2022-2025 | Tyrvaya |
| Harrow Eye, LLC | $88.57 | 2024-2025 | Vevye |
| Rxsight INC | $56.68 | 2021-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Thea Pharma INC. | $55.30 | 2023-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $47.67 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $42.06 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.93 | 2019-2020 | |
| Genmab U.S., INC. | $22.49 | 2023 | Tivdak |
| Astellas Pharma US INC | $18.87 | 2024 | Izervay |
| Shire North American Group INC | $17.89 | 2019 | |
| Amgen INC. | $15.98 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.